Tirzepatide Intermediate

Tirzepatide Intermediate

BOC- TYR(TBU)- AIB-GLU(OTBU)- GLY- OH,
CAS# 2682040-93-1
Fmoc - L- Lys [C20 - OtBu - Glu (OtBu) - AEEA- AEEA] - OH
CAS# 2460751-66-8 / 2915356-76-0
tBuO- C20- Glu (AEEA-AEEA-OH) - OtBu
CAS# 1188328-37-1
Fmoc - L- lle- Aib - OH
CAS# 2171139-20-9

White to off-white powder or crystalline solid, depending on specific intermediate stage.

Active Pharmaceutical Intermediate (API Intermediate) – for use in peptide chain elongation, protected amino acid coupling, or final deprotection and purification steps in the synthesis of Tirzepatide API.

Purity ≥ 95.0% (HPLC basis) for most peptide fragments

This intermediate is not intended for direct human use, but plays a critical role in the production of Tirzepatide, a dual GIP and GLP-1 receptor agonist developed for the treatment of:

Type 2 Diabetes Mellitus (T2DM):
Tirzepatide lowers blood glucose by enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, delaying gastric emptying, and improving insulin sensitivity. Clinical trials have demonstrated superior efficacy compared to current GLP-1 analogs, with greater reductions in HbA1c and fasting glucose levels.

Obesity and Chronic Weight Management:
Tirzepatide leads to significant and sustained weight reduction by regulating appetite centers in the brain, increasing satiety, and modifying fat metabolism. Its intermediate components are used to construct the complex, long-chain peptide structure that enables this dual incretin activity.

Ongoing Clinical Investigations:
Tirzepatide is also under evaluation for:
Cardiovascular risk reduction
Nonalcoholic fatty liver disease (NAFLD) and NASH
Polycystic ovary syndrome (PCOS)
Sleep apnea
Chronic kidney disease
These therapeutic targets rely on the bioactivity of the fully assembled peptide, synthesized through a stepwise combination of high-purity peptide intermediates like this product.

Conforms to internal synthesis control standards and quality specifications equivalent to research-grade or GMP-grade requirements for intermediates.

Store at -20°C in a sealed, light-resistant container.
Keep under dry, inert gas (nitrogen or argon) if applicable.
Avoid repeated freeze-thaw cycles. Use within defined shelf life for optimal integrity of the peptide bonds and protective groups.

Hot Tags: tirzepatide intermediate, China tirzepatide intermediate manufacturers, suppliers, pharmaceutical intermediates, MICA, 6 APA 6 Aminopenicillanic Acid 7177 48 2, 6-APA, 3-Benzoxazine-2, 2-Nitrobenzaldehyde